Long-term Follow-up Results of a Multi-institutional Phase 2 Study of Concurrent Chemoradiation Therapy for Locally Advanced Cervical Cancer in East and Southeast Asia

Kato, Shingo; Ohno, Tatsuya; Thephamongkhol, Kullathorn; Chansilpa, Yaowalak; Cao, Jianping; Xu, Ximing; Devi, C.R. Beena; Swee, Tang Tieng; Calaguas, M.J.; Reyes, Rey H. de los; Cho, Chul-Koo; Dung, To Anh; Supriana, Nana; Erawati, Dyah; Mizuno, Hideyuki; Nakano, Takashi; Tsujii, Hirohiko

doi:10.1016/j.ijrobp.2013.04.053

Cited by 31 publications

(35 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…5,17 In a phase II study of East and Southeast Asian patients who were younger than 70 years, the 5-year cumulative rates of grade Q2 and major late complications of the rectum were found to be 20.2% and 7.8%, respectively. 18 In light of these previous findings, the present study confirms that daily CCRT in elderly patients was feasible in terms of acute and late adverse effects. Generally, patients 80 years and older have heterogeneous concomitant conditions, and it is often difficult to evaluate well-being for these patients.…”

Section: Discussionsupporting

confidence: 85%

Daily Low-Dose Cisplatin-Based Concurrent Chemoradiotherapy for the Treatment of Cervical Cancer in Patients 70 Years or Older

Hanawa¹,

Mitsuhashi²,

Usui³

et al. 2015

International Journal of Gynecological Cancer

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 85%

Daily Low-Dose Cisplatin-Based Concurrent Chemoradiotherapy for the Treatment of Cervical Cancer in Patients 70 Years or Older

Hanawa¹,

Mitsuhashi²,

Usui³

et al. 2015

International Journal of Gynecological Cancer

View full text Add to dashboard Cite

show abstract

“…Previous studies demonstrated that distant metastasis was the major pattern of treatment relapses for patients with cervical cancer who received CCRT [7][8][9]. A study conducted in east and southeast Asia…”

Section: Introductionmentioning

confidence: 99%

Predictors of Distant Metastasis in Patients with Cervical Cancer Treated with Definitive Radiotherapy

Liu¹,

Meng²,

Wang³

et al. 2019

J. Cancer

View full text Add to dashboard Cite

Objective: To identify the predictors of distant metastasis in patients with cervical cancer treated with definitive radiotherapy and develop a model for predicting distant metastasis. Methods: We reviewed the clinical records of patients with cervical cancer treated with definitive radiotherapy (IMRT) at Peking Union Medical College Hospital between January 2011 and December 2015. Eligible patients were randomly assigned into model development cohort and validation cohort in a 2:1 ratio. Distant metastasis rate (DMR) was calculated with Kaplan-Meier method. Univariate and multivariate analyses using cox proportional hazard model was performed to identify the risk factors of distant relapse. Based on the identified risk factors for distant metastasis, a model for predicting distant metastasis was developed and validated. A two-side P＜0.05 was defined as statistically significant. Results: A total of 1193 patients were eligible for this analysis including 797 patients in the model development cohort and 396 patients in the validation cohort. The median follow-up durations of the model development cohort and the validation cohort were 28.7 months (range: 2.5-83.9 months) and 30.9 months (1.9-83.5 months). The 2-year distant metastasis rates (DMR) for patients in the model development cohort and validation cohort were 13.3% and 12.8%. Non-squamous cell carcinoma (non-Scc), common iliac lymph nodes metastasis (LNM) and bilateral pelvic LNM (PLNM) were identified as risk factors for distant metastasis. In the model development cohort, significant difference between high-risk group (with 2-3 risk factors) and low-risk group (with 0-1 risk factor) regarding DMR was observed (39.3% vs 19.3%, P<0.001). Similar conclusions were observed in the validation cohort (high-risk group vs low-risk group, 47.6% vs 10.9%, P<0.001) Conclusion: We successfully developed a model for predicting distant metastasis in patients with cervical cancer receiving definitive radiotherapy based on the three identified risk factors for distant metastasis. This model would help us distinguish patients with high risk of distant relapse from others.

show abstract

“…4,5 Although radical hysterectomy (RH) has traditionally been the standard treatment of early-stage cervical cancer, the National Comprehensive Cancer Network guidelines recommend cisplatin-based chemoradiation therapy (CRT) and as a primary treatment of International Federation of Gynecology and Obstetrics (FIGO) stage IIB cervical cancer. 6,7 However, CRT and adjuvant radiotherapy can both result in many serious complications that can destroy ovarian function and damage other organs. Many patients who receive CRT or adjuvant radiotherapy treatment experience conditions that can significantly affect their quality of life, including menopausal symptoms, sexual dysfunction, bowel complications, late urinary complications, pelvic fibrosis, and vaginal atrophy.…”

mentioning

confidence: 99%

Outcome of International Federation of Gynecology and Obstetrics Stage IIB Cervical Cancer From 2003 to 2012

Guo

Liu

Wang

et al. 2015

International Journal of Gynecological Cancer

View full text Add to dashboard Cite

show abstract

Long-term Follow-up Results of a Multi-institutional Phase 2 Study of Concurrent Chemoradiation Therapy for Locally Advanced Cervical Cancer in East and Southeast Asia

Cited by 31 publications

References 17 publications

Daily Low-Dose Cisplatin-Based Concurrent Chemoradiotherapy for the Treatment of Cervical Cancer in Patients 70 Years or Older

Daily Low-Dose Cisplatin-Based Concurrent Chemoradiotherapy for the Treatment of Cervical Cancer in Patients 70 Years or Older

Predictors of Distant Metastasis in Patients with Cervical Cancer Treated with Definitive Radiotherapy

Outcome of International Federation of Gynecology and Obstetrics Stage IIB Cervical Cancer From 2003 to 2012

Contact Info

Product

Resources

About